Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities. Commercial batches of the locally produced medicine have been delivered to the country’s healthcare facilities and are available for patients requiring urgent care.
NPO Petrovax Pharm is working to complete the transfer of the production technology in its entirety for Aktilyse (alteplase) used for acute ischemic stroke and heart attack treatment.
Production of these medicines will be fully localized in Russia starting in 2019. Boehringer Ingelheim and Petrovax Pharm are planning to gradually increase tenectaplase and alteplase production volumes as they believe that there will be significant export opportunities, primarily to the Eurasian Economic Union countries.